(Q36062926)

English

Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

9

object named as

Bernard A Fox

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

author name string

Dominik Rüttinger

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Natasja K van den Engel

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Hauke Winter

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Marcus Schlemmer

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Heike Pohla

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Stefanie Grützner

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Beate Wagner

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Dolores J Schendel

8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

K-W Jauch

10

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Rudolf A Hatz

11

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

14 September 2007

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Journal of Translational Medicine

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

43

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

14 September 2007

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

Manipulating the host response to autologous tumour vaccines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

T cell homeostatic proliferation elicits effective antitumor autoimmunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

Making room for T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

A fresh look at tumor immunosurveillance and immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

Augmentation of host immune responses to cancer: overcoming the barrier of tumor antigen-specific T-cell tolerance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

Thymic aging and T-cell regeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

2 October 2017

Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

11 July 2018

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

11 July 2018

Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

23 September 2018

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

23 September 2018

Development of antitumor immune responses in reconstituted lymphopenic hosts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

23 September 2018

Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2020458

23 September 2018

Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/17868452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17868452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17868452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17868452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17868452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1479-5876-5-43

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36062926&oldid=2198144618"